Plant Name: Lygodium japonicum
Taxonomic Information:
Plant ID: NPO1960
Plant Latin Name: Lygodium japonicum
Taxonomy Genus: Lygodium
Taxonomy Family: Lygodiaceae
Plant External Links:
NCBI TaxonomyDB:
13824
Plant-of-the-World-Online:
17143040-1
Used in Medicines:
Country/Region:
China; India; LaosTraditional Medicine System:
Indian Folk; TCMGeographical Distribution:
Georgia; South Africa; Philippines; India; United States; Australia; China; Vietnam; Laos; Sri Lanka; Japan; Taiwan; Thailand
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; | |
| CA2; CA12; CA14; CA7; | |
| PPARA; | |
| ALOX15; | |
| FABP3; RAB9A; FABP4; LMNA; FABP5; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.676E-10 | 3.650E-06 | CA12, CA14, CA2, CA7 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 2.146E-09 | 2.336E-05 | FABP3, FABP4, FABP5, FFAR4 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.649E-08 | 1.197E-04 | CA12, CA14, CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 5.431E-07 | 9.854E-04 | FABP3, FABP4, FABP5 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.254E-06 | 1.606E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.679E-06 | 2.031E-03 | CA12, CA2, CA7 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.541E-10 | 6.099E-09 | CA12, CA2, CA7, CA14 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 9.060E-08 | 1.087E-06 | FABP3, FABP4, FABP5, PPARA |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| NA: NA | Edema | NA | CA2; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
